Pharmaceuticals & Biotechnology | Pharma & Biotech Resources

Prof. Nair Rodriguez-Hornedo of the University of Michigan, discusses the latest successful strategies in making co-crystals, providing firsthand examples from the University's Department of Pharmaceutical Sciences. She offers her perspective on the most appropriate circumstances in

Pharma IQ are joined today by Dr. Ian Berry, Principal Scientist, Applications Developer and eScience Manager for Evotec UK, to discuss Evotec's experiences of piloting and integrating an ELN.     What Does The Future Hold For Electronic Lab Notebooks In 2012?

Pharma IQ are joined today by Dr. Ian Berry, Principal Scientist, Applications Developer and eScience Manager for Evotec UK, to discuss Evotec's experiences of piloting and integrating an ELN.     What Does The Future Hold For Electronic Lab Notebooks In 2012?

Spending less time on paperwork is a goal for all companies and the pharmaceutical industry is no different. In this Pharma IQ recording, John Trigg, Director, phaseFour Informatics caught up with Martin Vanderlaan, Director of Analytical Operations at Genentech, to discuss

Discover first hand how Roche deployed an ELN within the biopharmaceutical area. This interview with Ralph Haffner, Head of Biologic Research Informatics at Roche, documents the drivers, the planning and selection phase, through to the deployment and integration of an ELN. He also

Spending less time on paperwork is a goal for all companies and the pharmaceutical industry is no different. In this Pharma IQ recording, John Trigg, Director, phaseFour Informatics caught up with Martin Vanderlaan, Director of Analytical Operations at Genentech, to discuss

Patient safety is  a paramount concern for the pharmaceutical industry. Overlooked toxicity liability could not only put patient safety at risk, but also have huge financial implications for a pharmaceutical company. Dr. Fenghe Qiu, Principle Scientist & Leader of the

Supply chain plays a pivotal role, in balancing flexibility against a desired need for stability and standardisation. Madlene Dole, Head of NPhS Supply Chain, Novartis Pharma AG, joins us to discuss the challenges of tender business and global demand planning.

How can we widen the real of pre-competitive science? Dr. Johan Weigelt, Chief Scientist of the Structural Genomics Consortium at the Karolinska Institute, joined Pharma IQ to discuss the benefits for R&D restructuring, and how Public Private Partnerships (PPP) are enabling

Ensuring eCTD readiness is now critical for gaining first time market approval. Dr. Klaus Menges from the Division of Strategy and Planning, at the Federal Institute for Drugs and Medical Devices, Bfarm joins Pharma IQ to discuss strategies for successful eCTD lifecycle management.

The amorphous state is inherently instable. How do we keep amorphous forms from crystallising for as long as possible? Dr. Joseph Lubach from Genentech, joined Pharma IQ to discuss the challenges of physical and chemical stability, as well as techniques being implemented in the

Dr. Philippe Auby Senior Medical Director, Corporate ICR France & Paediatrics, Lundbeck joins Pharma IQ to share his insights on minimising the risk of regulatory censure in paediatric clinical development.  

Antonio Llamas, Regional Head of Operations in Spain & Portugal for Wyeth Research, joins us to discuss recent changes in the market, the process of selecting a CRO to partner with and subsequently maintaining a smooth relationship.

Vineet Kohli, Assistant Patent Counsel at Merck & Co., Inc., talks to Pharma IQ about the topics interesting him in the industry at present, the recent impacts in the law regarding patenting antibodies , and developments for the strategies of internal business units. All opinions

In this podcast Andrew Miller, Director of Clinical Information Standards at Astrazeneca, discusses data management and the efforts to standardise.